Evolent Level 1 Medical Oncology

Pathways and Low-Value Regimens

Soft Tissue Sarcoma – Angiosarcoma

Regimen Options

Last Updated: 06/03/2024 See Details

	Evolent Pathways	Febrile Neutropenic Risk	Emetogenic Risk	References
PRIOR TO LOCAL CONTROL OR POST-LOCAL CONTROL
Initial Therapy	docetaxel	Low	Low	NCCN Guidelines® for Soft Tissue Sarcoma V.2.2017. Nagano T, et al. Cancer. 2007;110(3):648-51.
	doxorubicin	High	High	NCCN Guidelines® for Soft Tissue Sarcoma V.2.2017. Sarcoma Meta-analysis Collaboration. Lancet. 1997;350(9092):1647-54. Pervaiz N, et al. Cancer. 2008;113(3):573-81.
	gemcitabine	Low	Low	NCCN Guidelines® for Soft Tissue Sarcoma V.2.2017. Stacchiotti S, et al. Ann Oncol. 2012;23(2):501-8.
	paclitaxel	Low	Low	NCCN Guidelines® for Soft Tissue Sarcoma V.2.2017. Schlemmer M, et al. Eur J Cancer. 2008;44(16):2433-6. Penel N, et al. J Clin Oncol. 2008;26(32):5269-74.
	vinorelbine	Low	Low	NCCN Guidelines® for Soft Tissue Sarcoma V.2.2017. Nasti G, et al. J Clin Oncol. 2000;18(7):1550-7.
Unresectable / Metastatic / Recurrent
Subsequent Therapy	docetaxel	Low	Low	NCCN Guidelines® for Soft Tissue Sarcoma V.2.2017. Nagano T, et al. Cancer. 2007;110(3):648-51.
	doxorubicin	High	High	NCCN Guidelines® for Soft Tissue Sarcoma V.2.2017. Sarcoma Meta-analysis Collaboration. Lancet. 1997;350(9092):1647-54. Pervaiz N, et al. Cancer. 2008;113(3):573-81.
	gemcitabine	Low	Low	NCCN Guidelines® for Soft Tissue Sarcoma V.2.2017. Stacchiotti S, et al. Ann Oncol. 2012;23(2):501-8.
	paclitaxel	Low	Low	NCCN Guidelines® for Soft Tissue Sarcoma V.2.2017. Schlemmer M, et al. Eur J Cancer. 2008;44(16):2433-6. Penel N, et al. J Clin Oncol. 2008;26(32):5269-74.
	vinorelbine	Low	Low	NCCN Guidelines® for Soft Tissue Sarcoma V.2.2017. Nasti G, et al. J Clin Oncol. 2000;18(7):1550-7.
	Best Supportive Care or Clinical Trial	NCCN Guidelines® for Supportive Care.

PRIOR TO LOCAL CONTROL OR POST-LOCAL CONTROL

Initial Therapy

Evolent Pathways

docetaxel

Febrile Neutropenic Risk

low

Emetogenic Risk

low

References

Evolent Pathways

doxorubicin

Febrile Neutropenic Risk

high

Emetogenic Risk

high

References

Evolent Pathways

gemcitabine

Febrile Neutropenic Risk

low

Emetogenic Risk

low

References

Evolent Pathways

paclitaxel

Febrile Neutropenic Risk

low

Emetogenic Risk

low

References

Evolent Pathways

vinorelbine

Febrile Neutropenic Risk

low

Emetogenic Risk

low

References

Unresectable / Metastatic / Recurrent

Subsequent Therapy

Evolent Pathways

docetaxel

Febrile Neutropenic Risk

low

Emetogenic Risk

low

References

Evolent Pathways

doxorubicin

Febrile Neutropenic Risk

high

Emetogenic Risk

high

References

Evolent Pathways

gemcitabine

Febrile Neutropenic Risk

low

Emetogenic Risk

low

References

Evolent Pathways

paclitaxel

Febrile Neutropenic Risk

low

Emetogenic Risk

low

References

Evolent Pathways

vinorelbine

Febrile Neutropenic Risk

low

Emetogenic Risk

low

References

Evolent Pathways

Best Supportive Care or Clinical Trial

References

	Regimen	Alternative	References
LOW VALUE REGIMENS (NON-PATHWAY) WITH SUPERIOR ALTERNATIVES
	pembrolizumab	Alternative: pazopanib

LOW VALUE REGIMENS (NON-PATHWAY) WITH SUPERIOR ALTERNATIVES

Regimen

** pembrolizumab **